MDLN
NasdaqMedline Inc.
Technology · Surgical & Medical Instruments & Apparatus
Research view
Fundamentals · SEC EDGAR · FY 2025-12-31
Revenue & Earnings — fiscal year
$23.2B
2023
$25.5B
2024
$28.4B
2025
Snapshot
SEC EDGAR · FY 2025-12-31Revenue$28.4B
Net Income$1.16T
Gross Profit$7.5B
Oper Income$2.2B
EPS (dil)$-0.01
Rev/sh—
FCF/sh—
Book/sh—
Gross M26.4%
Oper M7.8%
Profit M4069.4%
FCF M4.6%
ROE5999.2%
ROA3006.4%
ROIC6.9%
R&D/Rev0.3%
Rev Y/Y11.5%
Rev 3Y CAGR—
EPS Y/Y—
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y—
Current Ratio4.29
Quick Ratio2.37
Debt/Eq0.65
Int Coverage2.3×
Net Debt$10.6B
Total Debt$12.6B
Cash & Eq$1.9B
Total Assets$38.5B
Oper CF$1.7B
Capex$447.0M
Free CF$1.3B
Buybacks$33.0M
Equity$19.3B
Liabilities$19.2B
Shs Outstand—
SectorTechnology
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 3 FY| USD | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $23.2B | $25.5B | $28.4B |
| Gross Profit | $5.9B | $7.0B | $7.5B |
| Operating Income | $1.3B | $2.1B | $2.2B |
| Net Income | $234.0M | $1.2B | $1.16T |
| Diluted EPS | — | — | $-0.01 |
| Operating Cash Flow | $1.7B | $1.8B | $1.7B |
| Free Cash Flow | $1.4B | $1.4B | $1.3B |
COMMUNITY · $MDLN0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.